Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2.

Karan PattniDaniel HungerfordSarah AdamsIain BuchanChristopher P CheyneMarta García-FiñanaIan HallDavid M HughesChristopher E OvertonXingna ZhangKieran J Sharkey

Published in: BMC infectious diseases (2022)

Vaccine effectiveness for reducing susceptibility to SARS-CoV-2 infection shows noticeable improvement after receiving two doses of either vaccine. Findings also suggest that a full course of the Pfizer-BioNTech provides the optimal protection against infection with the Delta variant. This reinforces the need to complete the full course programme to maximise individual protection and reduce transmission.

Keyphrases

sars cov
randomized controlled trial
systematic review
respiratory syndrome coronavirus
study protocol